Indexado en

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Martinez, Antonio RamosAutor o CoautorFernandez-Cruz, AnaAutor o Coautor

Compartir

Faecal microbiota transplantation is a simple, effective and safe treatment in the management of C. difficile infection in daily clinical practice

Publicado en:ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 41 (4): 206-210 - 2023-04-03 41(4), DOI: 10.1016/j.eimc.2022.01.006

Autores: Ferre-Aracil, C; Martínez, IH; Mendoza, MIV; Martínez, AR; Rubio, EM; Fernández-Cruz, A; Royo, VM; García-Maseda, S; Romero, IS; Ruiz, RM; Panero, JLC

Afiliaciones

Resumen

Introduction: Faecal microbiota transplantation (FMT) is a treatment supported by wide scientific evidence and proved to be very effective in the management of Clostridioides difficile (CD) infection. The objective of this study is to analyze its effectiveness and safety in a real clinical practice setting.Methods: Retrospective, single-center and descriptive observational study in which all FMT performed between May 2016 and December 2020 were included. Technical success was defined as the successful administration of the fecal preparation in the patient's gastrointestinal tract and clinical success the disappearance of diarrhea in the first 72 h after the procedure with no relapse within the following 8 weeks after the therapy was started. Results: 15 FMT were performed in 13 patients. The mean age of the patients was 73 & PLUSMN; 19,4 years (range: 40-98 years); being 60% women. The indication for FMT was relapsing colitis due to CD in 84.6%. All FMTs were performed by colonoscopy and from related donors. With a first procedure, the TMF was effective in 11 of 13 patients (84.61%; 95% CI; 54.55-98.07). Time until resolution of symptoms was less than 48 h in all cases. Post-transplant follow-up was 25.66 & PLUSMN; 17.5 months. No significant short or long-term complications were recorded at follow-up.Conclusion: TMF is a simple, effective and safe procedure in CD infection, even in elderly patients or those with great comorbidities. Espana, S.L.U. All rights reserved.

Palabras clave